Biogen CEO Chris Viehbacher at the Financial Times' US Pharma and Biotech Summit, held in partnership with Endpoints News (Sarah Merians Photography for Endpoints News)
May 22, 2024 10:02 AM EDT
Deals

Bio­gen makes $1.15B buy for ARCH's HI-Bio to ex­pand im­munol­o­gy pipeline

Kyle LaHucik

Senior Reporter

Bio­gen is fur­ther ex­pand­ing be­yond its neu­ro­science roots and dip­ping more in­to im­munol­o­gy with a $1.15 bil­lion up­front ac­qui­si­tion of Hu­man Im­munol­o­gy Bio­sciences, or HI …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Evotec gains on Halozyme's takeover pro­pos­al

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Adap­ti­m­mune to 're­de­fine' it­self as a sar­co­ma biotech, cuts a third of staffers

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

ALX On­col­o­gy hires Genen­tech, Mi­rati vet as CMO; Af­ter Car­mot, Heather Turn­er has three new roles on tap

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times